Medical nanoparticles for next generation drug delivery to the lungs

Rijt, Sabine van; Bein, Thomas; Meiners, Silke

doi:10.1183/09031936.00212813

Cited by 127 publications

(86 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…15,16 Surface of NDDS may be modified with antibodies, tumor markers, fluorescent dyes, magnetic materials, carbohydrates, or mucoadhesive materials. 17 It was reported that surface coating of NDDS with mucoadhesive could provide additional advantages to NDDS such as protection against degradation, 18 localization of drug at the absorption window, 19 and sustaining drug effect. 20 Chitosan (CS) is a well-known cationic biodegradable polymer that was reported to enhance small intestine permeability.…”

Section: Introductionmentioning

confidence: 99%

Chitosan-coated diacerein nanosuspensions as a platform for enhancing bioavailability and lowering side effects: preparation, characterization, and ex vivo/in vivo evaluation

Allam¹,

Hamdallah²,

Abdallah³

2017

IJN

View full text Add to dashboard Cite

Nanodrug delivery systems have been widely reviewed for their use in several drug formulations to improve bioavailability, sustain effect, and decrease side effects of many candidate drugs. The objective of this study was to evaluate the potential of chitosan (CS)-coated nanosuspensions to enhance bioavailability and reduce the diarrheal side effect of diacerein (DCN) after oral administration. DCN nanosuspensions (DNS) were prepared by sonoprecipitation technique using different stabilizers at three different concentrations. The selected DNS with optimum particle size (PS), polydispersity index (PDI), and Zeta potential (ZP) was coated with three different concentrations of CS-coated DNS (CS-DNS) and screened. In vitro dissolution was performed for the selected lyophilized formulae and compared with DCN powder in addition to the assessment of drug crystallinity via scanning electron microscopy, X-ray powder diffraction, and differential scanning calorimetry. Ex vivo drug permeability using noneverted rat intestine, intraluminal content, and mucoadhesion evaluation was studied for nominated formulae in comparison to DCN suspension. Moreover, in vivo study, pharmacokinetic parameters, and evaluation of diarrheal potential were conducted after oral administration of selected formulae. Polyvinyl pyrrolidone (PVP)-stabilized DNS showed a significant increase ( P ≤0.05) in PS and PDI as the stabilizer concentration increased. PVP-stabilized DNS with the lowest CS concentration was protected from aggregation by lyophilization with mannitol. A remarked enhancement in dissolution parameters was observed in the nanocrystals’ formulae. Morphological examination and X-ray diffraction confirmed drug crystallinity. The intermediate permeation parameters of CS-DNS-F10, lowest rhein-to-DCN ratio in intraluminal content along with the highest percentage of mucoadhesive, could serve as a sustaining profile of coated formula. CS-DNS-F10 showed a significantly higher C max of 0.74±0.15 µg/mL at a delayed T max of 3.60±0.55 hours with a relative bioavailability of 172.1% compared to DCN suspension. CS-coated nanosuspensions could serve as promising revenue to enhance bioavailability and reduce the diarrheal side effect of DCN after oral administration.

show abstract

Section: Introductionmentioning

confidence: 99%

Chitosan-coated diacerein nanosuspensions as a platform for enhancing bioavailability and lowering side effects: preparation, characterization, and ex vivo/in vivo evaluation

Allam¹,

Hamdallah²,

Abdallah³

2017

IJN

View full text Add to dashboard Cite

show abstract

“…The first three Back to Basics reviews covered subjects as diverse as EGFR signalling [6], medical nanoparticles [7] and the latest advances in our knowledge of CFTR dysfunction [8]. This is an exciting new feature, and we look forward to watching it develop.…”

mentioning

confidence: 99%

The ambition of theEuropean Respiratory Journal: chapter 3

Humbert

Dinh-Xuan

Reeves³

et al. 2014

Eur Respir J

View full text Add to dashboard Cite

@ERSpublicationsThe ERS's flagship journal is making great headway http://ow.ly/DRPyzAs the title suggests, this is the third New Year "ambition" editorial of the current 5-year European Respiratory Journal (ERJ) editorial cycle. As we approach the half-way point, it is time not only to look back at 2014, but also to take stock of what has been achieved in the past 2 years and to set the agenda for what is still to be done. We will review the objectives we set in the previous editorials [1, 2] and look at some of the exceptional articles published in 2014. This editorial will be broader in scope than the previous two, looking not only at what the ERJ publishes, but also at how it publishes. The production and dissemination of the journal continues to develop, and we would like to highlight some exciting recent and forthcoming developments.

show abstract

“…[23] The lung is considered to be a particularly well-suited organ for local drug delivery as nanoparticles can be delivered via the trachea to the respiratory epithelium of the lung where they are efficiently taken up due to its large surface area, thin epithelium layer, and rich blood supply. [24] Therefore, we next evaluated intratracheal delivery of passively and actively targeted MSNs into the lungs using the previously reported Kras LA2 mutant mouse model for lung cancer. [25] This model displays clinically relevant cancer development compared to tumor cell injection models as tumors develop spontaneously and are heterogeneously distributed ( Figure 5A).…”

Section: Alveolar Macrophages Engulf Intratracheally Administered Msnmentioning

confidence: 99%

Organ-restricted vascular delivery of nanoparticles for lung cancer therapy

Bölükbas

Datz

Meyer‐Schwickerath

et al. 2020

Preprint

View full text Add to dashboard Cite

AbstractNanomedicines hold immense promise for a number of devastating diseases due to the ability to custom-design both the carrier and cargo. However, their clinical implementation has been hampered by physicochemical and biological barriers and off-target deposition which impair cell specific targeting, especially in internal organs. This study reports a new delivery approach using organ-restricted vascular delivery to allow for direct administration and recirculation of stimuli-responsive nanoparticles to promote cellular uptake into an organ of interest. Using this technique, nanoparticles reach the interior of dense tumors and are selectively taken up by lung cancer cells. Importantly, this surgical approach is essential as the same nanoparticles do not reach lung tumor cells upon systemic or intratracheal administration. Organ-restricted vascular delivery thus opens up new avenues for optimized nanotherapies for cancer and other diseases.

show abstract

Medical nanoparticles for next generation drug delivery to the lungs

Cited by 127 publications

References 84 publications

Chitosan-coated diacerein nanosuspensions as a platform for enhancing bioavailability and lowering side effects: preparation, characterization, and ex vivo/in vivo evaluation

Chitosan-coated diacerein nanosuspensions as a platform for enhancing bioavailability and lowering side effects: preparation, characterization, and ex vivo/in vivo evaluation

The ambition of theEuropean Respiratory Journal: chapter 3

Organ-restricted vascular delivery of nanoparticles for lung cancer therapy

Contact Info

Product

Resources

About